Chemistry of Heterocyclic Compounds

, Volume 53, Issue 3, pp 329–334

2-Arylazetidines as ligands for nicotinic acetylcholine receptors

  • Leonardo Degennaro
  • Marina Zenzola
  • Annunziatina Laurino
  • Maria Maddalena Cavalluzzi
  • Carlo Franchini
  • Solomon Habtemariam
  • Rosanna Matucci
  • Renzo Luisi
  • Giovanni Lentini
Article
  • 58 Downloads
Alternative and complementary procedures were adopted for preparing 2-arylazetidine derivatives in moderate to good yields. Preliminary biological evaluation of 2-arylazetidines as ligands of nicotinic acetylcholine receptors allowed to identify chloro-substituted analogs as the most interesting congeners. The title compounds may be considered as suitable hit compounds for developing new nicotinic acetylcholine receptor ligands that may be safer than the currently available drugs targeting nicotinic acetylcholine receptors. Our described synthetic approaches enable facile access to a large number of diversely decorated azetidines for studying the structure–activity relationships and for refining the toxico-pharmacological profile of these agents.

Keywords

azetidine ligand efficiency metrics lipophilicity neurodegeneration nicotinic acetylcholine receptors pain schizophrenia smoking cessation 

Supplementary material

10593_2017_2061_MOESM1_ESM.pdf (1.4 mb)
ESM 1(PDF 1445 kb)

References

  1. 1.
    Forgacs, P. B.; Bodis-Wollner, I. J. Neural Transm. 2004, 111, 1317.CrossRefGoogle Scholar
  2. 2.
    (a) Hurst, R.; Rollema, H.; Bertrand, D. Pharmacol. Ther. 2013, 137, 22. (b) Dineley, K. T.; Pandya, A. A.; Yakel, J. L. Trends Pharmacol. Sci. 2015, 36, 96.Google Scholar
  3. 3.
    (a) Decker, M. W.; Meyer, M. D.; Sullivan, J. P. Expert Opin. Invest. Drugs 2001, 10, 1819. (b) Zhang, X.; Xiao, H. S. Curr. Opin. Mol. Ther. 2005, 7, 532. (c) Vincler, M. Expert Opin. Invest. Drugs 2005, 14, 1191. (d) Nirogi, R.; Goura, V; Abraham, R.; Jayarajan, P. Eur. J. Pharmacol. 2013, 712, 22.Google Scholar
  4. 4.
    Picciotto, M. R.; Lewis, A. S.; van Schalkwyk, G. I.; Mineur, Y. S. Neuropharmacology 2015, 96, 235.CrossRefGoogle Scholar
  5. 5.
    Dwoskin, L. P.; Smith, A. M.; Wooters, T. E.; Zhang, Z.; Crooks, P. A.; Bardo, M. T. Biochem. Pharmacol. 2009, 78, 732.CrossRefGoogle Scholar
  6. 6.
    Sacco, K. A.; Bannon, K. L.; George, T. P. J. Psychopharmacology 2004, 18, 457.CrossRefGoogle Scholar
  7. 7.
    Quik, M.; Zhang, D.; Perez, X. A.; Bordia, T. Pharmacol. Ther. 2014, 144, 50.CrossRefGoogle Scholar
  8. 8.
    (a) Kumari, V.; Postma, P. Neurosci. Biobehav. Rev. 2005, 29, 1021. (b) de Leon, J.; Diaz, F. J.; Aguilar, M. C.; Jurado, D.; Gurpegui, M. Schizophr. Res. 2006, 86, 256.Google Scholar
  9. 9.
    Lloyd, G. K.; Williams, M. J. Pharmacol. Exp. Ther. 2000, 292, 461.Google Scholar
  10. 10.
    McEvoy, J. P.; Allen, T. B. Curr. Drug Targets: CNS Neurol. Disord. 2002, 1, 433.Google Scholar
  11. 11.
    Czodrowski, P.; Mallinger, A.; Wienke, D.; Esdar, C.; Pöschke, O.; Busch, M.; Rohdich, F.; Eccles, S. A.; Ortiz-Ruiz, M.-J.; Schneider, R.; Raynaud, F. I.; Clarke, P. A.; Musil, D.; Schwarz, D.; Dale, T.; Urbahns, K.; Blagg, J.; Schiemann, K. J. Med. Chem. 2016, 59, 9337.CrossRefGoogle Scholar
  12. 12.
    Jacobson, T. A.; Ito, M. K.; Maki, K. C.; Orringer, C. E.; Bays, H. E.; Jones, P. H.; McKenney, J. M.; Grundy, S. M.; Gill, E. A.; Wild, R. A.; Wilson, D. P.; Brown, W. V. J. Clin. Lipidol. 2015, 9, 129.CrossRefGoogle Scholar
  13. 13.
    López-Muñoz, F.; Alamo, C. Curr. Pharm. Des. 2009, 15, 1563.CrossRefGoogle Scholar
  14. 14.
    Changeux, J. P.; Edelstein, S. J. Neuron 1998, 21, 959.CrossRefGoogle Scholar
  15. 15.
    (a) Brandi, A.; Cicchi, S.; Cordero, F. M. Chem. Rev. 2008, 108, 3988. (b) Han, J.-Q.; Zhang, H.-H.; Xu, P.-F.; Luo, Y.-C. Org. Lett. 2016, 18, 5212. (c) Takizawa, S.; Arteaga, F. A.; Yoshida, Y.; Suzuki, M.; Sasai, H. Org. Lett. 2013, 15, 4142. (d) Das, B.; Balasubramanyam, P.; Veeranjaneyulu, B.; Reddy, G. C. J. Org. Chem. 2009, 74, 9505.Google Scholar
  16. 16.
    (a) Degennaro, L.; Zenzola, M.; Trinchera, P.; Carroccia, L.; Giovine, A.; Romanazzi, G.; Falcicchio, A.; Luisi, R. Chem. Commun. 2014, 50, 1698. (b) Zenzola, M.; Degennaro, L.; Trinchera, P.; Carroccia, L.; Giovine, A.; Romanazzi, G.; Mastrorilli, P.; Rizzi, R.; Pisano, L.; Luisi, R. Chem.–Eur. J. 2014, 20, 12190. (c) De Angelis, S.; De Renzo, M.; Carlucci, C.; Degennaro, L.; Luisi R. Org. Biomol. Chem. 2016, 14, 4304.Google Scholar
  17. 17.
    (a) Parisi, G.; Zenzola, M.; Capitanelli, E.; Carlucci, C.; Romanazzi, G.; Pisano, L.; Degennaro, L.; Luisi, R. Pure Appl. Chem. 2016, 88, 631. (b) Parisi, G.; Capitanelli, E.; Pierro, A.; Romanazzi, G.; Clarkson, G. J.; Degennaro, L.; Luisi, R. Chem. Commun. 2015, 51, 15588. (c) De Ceglie, M. C.; Musio, B.; Affortunato, F.; Moliterni, A.; Altomare, A.; Florio, S.; Luisi, R. Chem.–Eur. J. 2011, 17, 286.Google Scholar
  18. 18.
    (a) Hopkins, A. L.; Keserü, G. M.; Leeson, P. D.; Rees, D. C.; Reynolds, C. H. Nat. Rev. Drug Discovery 2014, 13, 105. (b) Gualdani, R.; Cavalluzzi, M. M.; Lentini, G. Curr. Med. Chem. 2016, 23, 2289. (c) Gualdani, R.; Cavalluzzi, M. M.; Lentini, G.; Habtemariam, S. Molecules 2016, 21, 1530.Google Scholar
  19. 19.
    Hogg, R. C.; Bertrand, D. Biochem. Pharmacol. 2007, 73, 459.CrossRefGoogle Scholar
  20. 20.
    Carocci, A.; Lentini, G.; Catalano, A.; Cavalluzzi, M. M.; Bruno, C.; Muraglia, M.; Colabufo, N. A.; Galeotti, N.; Corbo, F.; Matucci, R.; Ghelardini, C.; Franchini, C. ChemMedChem 2010, 5, 696.CrossRefGoogle Scholar
  21. 21.
    Lo, M. M.-C., Fu, G. C. Tetrahedron 2001, 57, 2621.CrossRefGoogle Scholar
  22. 22.
    Roselli, M.; Lentini, G.; Habtemariam, S. Phytother. Res. 2012, 26, 908.CrossRefGoogle Scholar
  23. 23.
    Manni, M. E.; Bigagli, E.; Lodovici, M.; Zazzeri, M.; Raimondi, L. Pharmacol. Res. 2012, 65, 465.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Leonardo Degennaro
    • 1
  • Marina Zenzola
    • 1
  • Annunziatina Laurino
    • 2
  • Maria Maddalena Cavalluzzi
    • 1
  • Carlo Franchini
    • 1
  • Solomon Habtemariam
    • 3
  • Rosanna Matucci
    • 2
  • Renzo Luisi
    • 1
  • Giovanni Lentini
    • 1
  1. 1.Department of Pharmacy – Drug SciencesUniversity of Studies of Bari Aldo MoroBariItaly
  2. 2.Department of NeuroscienceArea del Farmaco e Salute del Bambino (NEUROFARBA)FirenzeItaly
  3. 3.Pharmacognosy Research Laboratories, Medway School of ScienceUniversity of GreenwichKentUnited Kingdom

Personalised recommendations